tradingkey.logo

Zoetis Inc

ZTS
120.980USD
+2.320+1.96%
Close 12/15, 16:00ETQuotes delayed by 15 min
53.41BMarket Cap
20.37P/E TTM

Zoetis Inc

120.980
+2.320+1.96%
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison

TradingKey Stock Score of Zoetis Inc

Currency: USD Updated: 2025-12-15

Key Insights

Zoetis Inc's fundamentals are relatively healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 33/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 164.86.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Zoetis Inc's Score

Industry at a Glance

Industry Ranking
33 / 159
Overall Ranking
101 / 4589
Industry
Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Analyst Rating

Based on 20 analysts
Buy
Current Rating
164.863
Target Price
+39.53%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Zoetis Inc Highlights

StrengthsRisks
Zoetis Inc. is a global animal health company. The Company is focused on the discovery, development, manufacture and commercialization of medicines, vaccines, diagnostic products and services, biodevices, genetic tests and precision animal health. The Company operates through two segments: the United States (U.S.) and International. Within each of these operating segments, it offers a diversified product portfolio, including parasiticides, vaccines, dermatology, anti-infectives, pain and sedation, other pharmaceutical, and animal health diagnostics, for both companion animal and livestock customers. It directly markets its products in approximately 45 countries across North America, Europe, Africa, Asia, Australia and South America. The Company is engaged in commercializing products across eight species: dogs, cats and horses (collectively, companion animals) and cattle, poultry, swine, fish and sheep (collectively, livestock).
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 9.26B.
High Dividend
The company is a high dividend payer, with the latest dividend payout ratio of 32.66%.
Stable Dividend
The company has regularly paid dividends over the past 5 years, with the latest dividend payout ratio of 32.66%.
Undervalued
The company’s latest PE is 20.37, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 435.62M shares, decreasing 0.32% quarter-over-quarter.
Held by Mairs and Power
Star Investor Mairs and Power holds 7.22K shares of this stock.

Financial Health

Currency: USD Updated: 2025-12-15

The current financial score of Zoetis Inc is 8.99, ranking 22/159 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 2.40B, representing a year-over-year increase of 0.50%, while its net profit experienced a year-over-year increase of 5.72%.

Score

Industry at a Glance

Previous score
8.99
Change
0

Financials

6.88

Key Metrics

Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.

Quality of Earnings

8.72

Operational Efficiency

10.00

Growth Potential

10.00

Shareholder Returns

9.37

Zoetis Inc's Company Valuation

Currency: USD Updated: 2025-12-15

The current valuation score of Zoetis Inc is 5.60, ranking 146/159 in the Pharmaceuticals industry. Its current P/E ratio is 20.37, which is 105.96% below the recent high of 41.95 and 4.32% above the recent low of 19.49.

Score

Industry at a Glance

Previous score
5.60
Change
0

Valuation Dimensions

P/E
P/B
P/S
P/CF
Industry Ranking 33/159
Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2025-12-15

The current earnings forecast score of Zoetis Inc is 8.10, ranking 54/159 in the Pharmaceuticals industry. The average price target for Zoetis Inc is 165.00, with a high of 200.00 and a low of 130.00.

Score

Industry at a Glance

Previous score
8.10
Change
0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 20 analysts
Buy
Current Rating
164.863
Target Price
+39.53%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell

Peer Comparison

171
Total
6
Median
8
Average
Company name
Ratings
Analysts
Zoetis Inc
ZTS
20
Biogen Inc
BIIB
36
Amgen Inc
AMGN
35
Vertex Pharmaceuticals Inc
VRTX
33
Eli Lilly and Co
LLY
33
AbbVie Inc
ABBV
32
1
2
3
...
34

Financial Forecasting

EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-12-15

The current price momentum score of Zoetis Inc is 7.18, ranking 85/159 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 128.62 and the support level at 114.29, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score
6.84
Change
0.34

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators

The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators
Sell(2)
Neutral(3)
Buy(1)
Indicators
Value
Direction
MACD(12,26,9)
0.778
Neutral
RSI(14)
44.328
Neutral
STOCH(KDJ)(9,3,3)
37.228
Buy
ATR(14)
3.316
Low Volatility
CCI(14)
-25.580
Neutral
Williams %R
61.472
Sell
TRIX(12,20)
-0.346
Sell
StochRSI(14)
100.000
Overbought
Moving Average
Sell(4)
Neutral(0)
Buy(2)
Indicators
Value
Direction
MA5
118.224
Buy
MA10
119.535
Buy
MA20
121.060
Sell
MA50
130.808
Sell
MA100
140.262
Sell
MA200
149.745
Sell

Institutional Confidence

Currency: USD Updated: 2025-12-15

The current institutional shareholding score of Zoetis Inc is 10.00, ranking 1/159 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 98.29%, representing a quarter-over-quarter increase of 0.29%. The largest institutional shareholder is The Vanguard, holding a total of 42.10M shares, representing 9.55% of shares outstanding, with 2.84% increase in holdings.

Score

Industry at a Glance

Previous score
10.00
Change
0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name
Shares Held
Chg %
The Vanguard Group, Inc.
Star Investors
41.69M
+0.79%
BlackRock Institutional Trust Company, N.A.
22.66M
-2.15%
State Street Investment Management (US)
19.74M
-0.30%
State Farm Insurance Companies
16.84M
-0.20%
Geode Capital Management, L.L.C.
11.08M
+0.87%
Wellington Management Company, LLP
8.89M
+46.56%
Polen Capital Management, LLC
8.42M
-4.27%
Morgan Stanley Investment Management Ltd. (UK)
6.75M
+209.96%
Wells Fargo Advisors
5.83M
-3.00%
Norges Bank Investment Management (NBIM)
5.19M
+2.60%
1
2

Risk Assessment

Currency: USD Updated: 2025-12-15

The current risk assessment score of Zoetis Inc is 7.45, ranking 41/159 in the Pharmaceuticals industry. The company's beta value is 0.98. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.

Score

Industry at a Glance

Previous score
7.45
Change
0
Beta vs S&P 500 index
0.98
VaR
+2.67%
240-Day Maximum Drawdown
+34.11%
240-Day Volatility
+32.59%

Return

Best Daily Return
60 days
+5.32%
120 days
+5.32%
5 years
+7.09%
Worst Daily Return
60 days
-13.78%
120 days
-13.78%
5 years
-13.78%
Sharpe Ratio
60 days
-2.08
120 days
-1.77
5 years
+0.02

Risk Assessment

Maximum Drawdown
240 days
+34.11%
3 years
+42.15%
5 years
+53.14%
Return-to-Drawdown Ratio
240 days
-0.75
3 years
-0.22
5 years
-0.06
Skewness
240 days
-1.66
3 years
-0.70
5 years
-0.63

Volatility

Realised Volatility
240 days
+32.59%
5 years
+28.91%
Standardised True Range
240 days
+3.13%
5 years
+3.31%
Downside Risk-Adjusted Return
120 days
-185.94%
240 days
-185.94%
Maximum Daily Upside Volatility
60 days
+30.54%
Maximum Daily Downside Volatility
60 days
+33.02%

Liquidity

Average Turnover Rate
60 days
+0.69%
120 days
+0.67%
5 years
--
Turnover Deviation
20 days
+19.58%
60 days
+19.12%
120 days
+15.09%

Peer Comparison

Pharmaceuticals
Zoetis Inc
Zoetis Inc
ZTS
7.89 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Prestige Consumer Healthcare Inc
Prestige Consumer Healthcare Inc
PBH
8.75 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Collegium Pharmaceutical Inc
Collegium Pharmaceutical Inc
COLL
8.71 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Regeneron Pharmaceuticals Inc
Regeneron Pharmaceuticals Inc
REGN
8.67 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
United Therapeutics Corp
United Therapeutics Corp
UTHR
8.65 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Catalyst Pharmaceuticals Inc
Catalyst Pharmaceuticals Inc
CPRX
8.61 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more

FAQs

How does TradingKey generate the Stock Score of Zoetis Inc?

The TradingKey Stock Score provides a comprehensive assessment of Zoetis Inc based on 34 indicators derived from over 100 underlying data points.
These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of Zoetis Inc’s performance and outlook.

How do we generate the financial health score of Zoetis Inc?

To generate the financial health score of Zoetis Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns.
By integrating these comprehensive data, the financial health score not only reflects Zoetis Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of Zoetis Inc.

How do we generate the company valuation score of Zoetis Inc?

To generate the company valuation score of Zoetis Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare Zoetis Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value.
By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of Zoetis Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of Zoetis Inc.

How do we generate the earnings forecast score of Zoetis Inc?

To calculate the earnings forecast score of Zoetis Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:
Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.
Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.
By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.
Comparing these indicators against peers provides context for the stock’s performance and helps anchor more realistic expectations.
These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on Zoetis Inc’s future.

How do we generate the price momentum score of Zoetis Inc?

When generating the price momentum score for Zoetis Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.
Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.
This comprehensive approach can reflect market sentiment and enable rational forecasts of Zoetis Inc’s prices. A higher score indicates a more stable short-term price trend for Zoetis Inc.

How do we generate the institutional confidence score of Zoetis Inc?

To generate the institutional confidence score of Zoetis Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about Zoetis Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of Zoetis Inc.

How do we generate the risk management score of Zoetis Inc?

To assess the risk management score of Zoetis Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.
The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.
These indicators together provide a multi-dimensional understanding of Zoetis Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of Zoetis Inc.
KeyAI